Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1872-034X.2011.00873.x/abstract

Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms

and mutation sites

Lihui Deng1,2, Hong Tang1,2,

*Article first published online: 15 SEP 2011

DOI: 10.1111/j.1872-034X.2011.00873.x

© 2011 The Japan Society of Hepatology

Issue

Hepatology Research

Early View (Online Version of Record published before inclusion in an issue)

ABSTRACT

Nucleos(t)ide analogs (NAs) have become the mainstream drugs for the treatment

of chronic hepatitis B virus infection. Drug resistance to NAs, however, has

posed a major obstacle in obtaining sustained viral suppression. Standardized

definitions of terms and nomenclature in discussing NAs resistance have been

proposed. Drug resistance to NAs is produced by a combination of viral, host and

antiviral drug factors. A detailed understanding of the mechanisms and effects

of mutation sites that cause resistance to NAs is important for the design of

rational treatment and management of patients with existing drug resistance.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1872-034X.2011.00873.x/abstract

Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms

and mutation sites

Lihui Deng1,2, Hong Tang1,2,

*Article first published online: 15 SEP 2011

DOI: 10.1111/j.1872-034X.2011.00873.x

© 2011 The Japan Society of Hepatology

Issue

Hepatology Research

Early View (Online Version of Record published before inclusion in an issue)

ABSTRACT

Nucleos(t)ide analogs (NAs) have become the mainstream drugs for the treatment

of chronic hepatitis B virus infection. Drug resistance to NAs, however, has

posed a major obstacle in obtaining sustained viral suppression. Standardized

definitions of terms and nomenclature in discussing NAs resistance have been

proposed. Drug resistance to NAs is produced by a combination of viral, host and

antiviral drug factors. A detailed understanding of the mechanisms and effects

of mutation sites that cause resistance to NAs is important for the design of

rational treatment and management of patients with existing drug resistance.